INBUILD study was an all cause ILD nintedanib RCT (n=663). Subanalysis of 89 RA-ILD pts showed FVC decline (@ 52 wks) was −82.6 mL/yr on NIN vs −199.3 mL/yr on PBO (p=.037). NIN diarrhea in 62%; & AE discontinuation in 24% https://t.co/nWuGx6wjB2 https://t.co/LVwy1Z5TL3